

May 9, 2023



## iBio to Participate in the JMP Securities Life Sciences Conference

BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- [iBio, Inc.](https://www.ibioinc.com) (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, announced today that its Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 12:00 p.m. Eastern Time at the New York Hilton Midtown.

The fireside chat will be broadcast live and archived on the Company's website at [www.ibioinc.com](https://www.ibioinc.com) under "News & Events" in the Investors section.

### About iBio, Inc.

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio's mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit [www.ibioinc.com](https://www.ibioinc.com).

### Contact:

Stephen Kilmer  
iBio, Inc.  
Investor Relations  
(646) 274-3580  
[skilmer@ibioinc.com](mailto:skilmer@ibioinc.com)



Source: iBio, Inc.